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Key questions
What is already known?
 ► Private healthcare providers (HCPs), which include 
formal and informal providers, are widely used in 
low-income and middle-income countries, and are 
not well-regulated or monitored.
 ► Inappropriate use of antibiotics by informal providers 
is a global concern as this may be driving antibiotic 
resistance.
What are the new findings?
 ► Informal HCPs, including those that are ‘invisible’ 
because they have no marked healthcare facility, are 
commonly used for purchasing antibiotics in peri-ur-
ban Cambodia.
 ► They are trusted providers of medicines, despite 
communities knowing that they do not hold the re-
quired qualifications to sell medicines, because of 
their convenience and propensity to overmedicate to 
provide quick relief.
What do the new findings imply?
 ► Because communities want easy access to antibi-
otics, there remains a demand for services provided 
by invisible and informal HCPs that have inadequate 
knowledge of antibiotic use.
 ► It is challenging but important for public health 
agencies to engage with informal HCPs that are 
‘invisible’.
AbsTrACT
background Global attention to antimicrobial resistance 
has increased interest in tackling the widespread 
inappropriate dispensing of antibiotics by informal, for-profit 
healthcare providers (HCPs). We provide new evidence on 
an understudied group of informal HCPs: invisible medicine 
sellers (IMS) who operate without any marked facility. We 
investigated factors that influence community decisions 
on which HCPs to purchase medicines from, focusing 
on reasons for using IMS, and compared different HCPs’ 
knowledge of antibiotic use.
Methods We conducted community focus group discussions 
(FGDs) in seven purposively selected villages representing 
high and low informal HCPs use in two peri-urban districts 
in Phnom Penh, Cambodia. Using information from the 
FGDs to identify HCPs that sell medicines, we interviewed 
35 participants: 21 HCPs (including five IMS) and 14 key 
informants, including government HCPs and village leaders. 
We adopted an interpretative approach and conducted a 
thematic analysis.
results Community members typically knew of several 
formal and informal HCPs selling medicines nearby, and IMS 
were common, as were doctors that sell medicines covertly. 
Two factors were most salient in influencing the choice 
of HCP for medicine purchasing. The first was trust in the 
effectiveness of medicines provided, judged by the speed 
of symptomatic relief. This pushed HCPs to provide several 
medicines, including antibiotics, at the first consultation. 
The second was the convenience offered by IMS and other 
informal HCPs: supplying medicines when other facilities are 
closed, accepting delayed payments, providing incomplete 
courses of medication and selling human antibiotics for 
animal use.
Conclusion This first study focusing on IMS indicates that 
it is important, but challenging, for public health agencies to 
engage with them to reduce inappropriate use of antibiotics. 
Although public health facilities must fill some gaps that 
informal HCPs are currently addressing, such as access 
to medicines at night, reducing demand for unnecessary 
antibiotics is also critical.
InTroduCTIon
Although there are opposing views on the 
optimal role of the private healthcare sector, it 
is clear that global constraints on government 
investment in public services are resulting in 
private healthcare providers (HCPs) playing a 
greater role in health service delivery to rich 
and poor populations.1–4 Private HCPs are 
used substantially more than public HCPs in 
many low-income and middle-income coun-
tries (LMIC). Their dominance is particularly 
pronounced in many Asian countries.3–7 This 
heterogeneous group encompasses tradi-
tional healers as well as allopathic ‘western 
medicine’ providers, of which some are 
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Figure 1 Position of invisible healthcare providers among different types of for-profit healthcare providers.
highly qualified and officially licenced by the govern-
ment (referred to as formal providers) while others do 
not have qualifications or licensing that is recognised by 
local authorities (referred to as informal providers).3 8–10
Evidence suggests that informal HCPs are the least 
trained and monitored group within LMIC health 
systems.11 Several studies from Asian LMIC indicate that 
informal HCPs lack the knowledge required to provide 
basic curative services, and a systematic review of 122 
studies identified important recurring findings: informal 
providers typically show poor adherence to national 
guidelines, particularly in relation to inappropriate 
medicine provision, and their quality of care affects large 
populations since they are often a major component 
of the LMIC health systems.10–14 Despite the evidence 
on poor technical quality of care provided by informal 
HCPs, finding effective regulatory approaches in LMIC 
contexts continues to be incredibly challenging.15 16 Part 
of the reason for this is that regulatory interventions often 
do not adequately consider local health system dynamics 
and complexities, including two practical issues which we 
focus on in this study: first, some informal HCPs operate 
from locations that are difficult to identify, and second, 
there is often strong community demand for the services 
provided by informal HCPs.
Invisible medicine sellers
In this study, we further divide informal providers into 
two categories: visible HCPs, who provide health services 
within a physical space that is signposted and designed 
for health services, and invisible HCPs, who provide 
health services without having a marked and specifically 
designated outlet for this purpose (figure 1). Invisible 
HCPs have been insufficiently addressed by researchers 
and policymakers, largely because it is inherently difficult 
for authorities and researchers to identify them through 
standard surveys and inspections; therefore, their positive 
and negative contribution to local health service provi-
sion remains hidden. We specifically focus on invisible 
HCPs who engage in inappropriate dispensing of medi-
cines, and who we refer to as invisible medicine sellers 
(IMS). Although any dispensing of medicines without 
establishing clinical need could pose a risk to patients, 
inappropriate provision of antibiotics is currently a 
major global concern owing to the scale of morbidity and 
mortality that is predicted to be caused by antimicrobial 
resistance (AMR).17 There is some evidence to suggest 
that for-profit HCPs, including IMS, excessively use anti-
biotics, and are driven partly by the desire to maximise 
profits and meet patient demands.18–24 However, no 
studies, to the best of our knowledge, have undertaken 
an in-depth analysis of IMS and their use of antibiotics 
in any country, including how IMS become trusted 
providers of medicine—thereby generating community 
demand for their services.
Conceptualisations of trust in HCPs
As part of our analysis, we explored the concept of trust 
surrounding different types of HCPs, particularly those 
that are known to have no medical qualifications or 
licensing. Trust is a complex phenomenon rooted in 
subconscious thoughts that are difficult for individuals to 
recognise.25 Möllering conceptualises trust as a process 
consisting of three key elements: expectation, interpre-
tation and suspension. He defines expectation as the 
outcome at the end of an interaction, which is preceded 
by the combination of interpretation and suspension. 
Interpretation refers to experiences that provide rational 
justification for trusting or not trusting a person or an 
institution. The third component, suspension, is the least 
explored; it refers to emotional bases of trust that move 
away from rational choices. This has also been referred 
by Simmel, who greatly influenced Möllering, as a myste-
rious sense of faith in another person.26 Throughout the 
paper, we differentiate between these three elements of 
trust, and will reflect on which of these are more present 
in the Cambodian context.
study setting and objectives
Cambodia is a lower-middle-income country with a 
population of approximately 16 million.18 Phnom Penh, 
Cambodia’s capital, is the most densely populated city 
in the country, with a population of 1.5 million. Phnom 
Penh is divided into 14 khans, composed of 953 villages. 
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Figure 2 Map of hospitals and pharmacies in Phnom Penh 
with Khan Sen Sok (orange) and Khan Po Sen Chey (pink) 
highlighted.
Each khan and each village has a leader, and clusters 
of villages are served by a local government-run health 
centre.
Cambodia’s public health system was weakened 
during the Khmer Rouge regime and the consequent 
Cambodian Civil War due to the systematic killing of 
intellectuals—including trained health professionals; 
consequently, the private health sector is very promi-
nent.27 Nearly 70% of Cambodian patients first seek treat-
ment in the private sector, and private medicine sellers 
are the preferred HCPs for the majority of those who are 
ill.28 The Medicines Policy of the Kingdom of Cambodia 
states that no medicines will be distributed through unau-
thorised outlets, and lays out clear regulations regarding 
sales of medicines: medicines are to be sold in phar-
macies with trained pharmacists, and patients cannot 
obtain restricted medicines, such as antibiotics, without 
a prescription.29 Doctors are only allowed to sell a limited 
set of emergency medicines, although there is a lack of 
clarity around these rules.
Cambodia serves as a useful setting to study IMS and 
their potential role in AMR, as much of the action on 
unlicensed drug sellers in Cambodia has been triggered 
by concerns about AMR; this issue gained global atten-
tion when artemisinin resistance was discovered on 
the Cambodia–Thailand border in 2009, and resulted 
in high-profile ‘crack downs’ on unlicensed medicine 
shops until the number was reported to be close to zero 
in 2011.30 31 In 2014, Cambodia became one of the first 
countries in the Western Pacific Region to develop a 
national policy on AMR.32 33 However, drafting of the 
national action plan with concrete steps on addressing 
inappropriate use of antibiotics has been challenging 
since antibiotics are readily available without a prescrip-
tion from formal and informal HCPs, and are some-
times substandard or false.34–37 Although information on 
licensed pharmacies is regularly updated by the Depart-
ment of Drugs and Food in the Ministry of Health, the 
data only include those that are registered and there 
are reports of the continued existence and utilisation of 
unlicensed medicine shops.38 39 It is clear that licensed 
pharmacies are concentrated in the most central khans 
of Phnom Penh; unlicensed medicine shops are more 
prevalent in outskirts of the city, and remain the main 
source of care for those below the poverty line.40–42 Very 
little is known about the presence and role of IMS within 
this wider group of unregistered medicine sellers.
In light of the dearth of research on informal (partic-
ularly invisible) HCPs and their role as sellers of antibi-
otics, we investigated factors influencing the choice of 
HCP to purchase medicines for minor ailments, focusing 
particularly on reasons for using IMS, and on identifying 
different sources of trust in specific providers of medi-
cine. We additionally compared HCPs’ knowledge of the 
correct use of antibiotics, seeking to understand whether 
IMS present a greater risk of inappropriately dispensing 
antibiotics.
MeTHods
study population
This study was conducted in seven villages in two peri-
urban khans on the outskirts of Phnom Penh: Po Sen 
Chey and Sen Sok. These khans, like others outside of 
the central part of Phnom Penh, have very few registered 
pharmacies, as illustrated in figure 2. Purposive selection 
of villages for the qualitative investigation was primarily 
based on data collected by a non-governmental service 
delivery organisation, Operation ASHA (OpASHA). 
OpASHA community health workers conduct door-to-
door health screening, and as part of this screening, 
they undertook a rapid assessment of community health-
care-seeking behaviour. During the rapid assessment, five 
men and five women in each village were asked a series 
of questions including one about the use of informal 
HCPs for accessing medicines. We reviewed results of this 
rapid assessment across 122 villages in the study khans, 
and selected villages that represented low and high use 
of informal HCPs for buying medicines.43 Our selected 
villages represented a range such that 25%–80% of the 
respondents reported buying medicine from informal 
HCPs. Purposive selection also took the willingness of the 
village leader to support the study into account, in line 
with our ethical approval form. Village leaders contacted 
male and female participants and asked if they would like 
to participate in the focus group, which ensured a variety 
of occupations and age ranges.
data collection
Focus group discussions (FGDs) were conducted with 
community members from the seven selected villages. 
FGDs 1, 3, 4 and 7 were conducted in Po Sen Chey, and 
FGDs 2, 5 and 6 were conducted in Sen Sok. A topic 
guide was used to facilitate discussions on where to seek 
care when people are sick with minor ailments and 
participants’ views about types of HCPs. We worked as 
a group to translate and appropriately phrase questions 
in Khmer, and piloted the data collection process in 
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one village. FGDs were led by an experienced bilingual 
facilitator in Khmer, who thoroughly explained who the 
researchers were and the purpose of their work, and 
two members from the research team (a mix of male 
and female researchers, with an MSc or PhD) observed 
the discussion and took detailed notes. No one other 
than participants and researchers was present during 
the FGDs. The research team worked with the village 
leaders to select 6–8 participants in each village, aiming 
for an even distribution of age and sex. FGDs were 
audio-recorded following consent, and typically lasted 
45 min.
The details of every provider selling medicines that 
FGD participants mentioned were noted, including 
the location and demographic characteristics. Immedi-
ately following each FGD, the research team sought to 
locate these HCPs and approach them for an interview. 
We also interviewed public health centre staff, and khan 
and village leaders. The semi-structured interviews were 
conducted by two Cambodian researchers from our team 
of six (SS, SB, SC, CP, SH and SP), and were facilitated by 
a topic guide that explored perceived patient behaviour, 
referral processes, reasons interviewees think patients 
use different for-profit HCPs, knowledge of regulations 
related to medicine sales, and use of antibiotics.
Qualitative data management and analysis
Interviews and FDGs were recorded and detailed field 
notes were taken, except when audio recording was 
not allowed by an interviewee. English language audio 
recordings were transcribed by a researcher (SR), and 
Khmer language audio recordings were translated and 
transcribed by external professional translators. After 
translation, Khmer language interviews were reviewed by 
University of Health Sciences researchers (SS and SC). 
Participants were de-identified and numbered in the 
transcripts. We conducted a thematic analysis employing 
an interpretive approach in which identified themes 
are supported by excerpts from the raw data to ensure 
that data interpretation remains directly linked to the 
words of the participants.44 This thematic analysis began 
by convening all authors closely involved in data collec-
tion (SS, SB, SR, MK, SP and SC) to discuss and agree on 
the emerging themes after reading the transcripts, then 
each transcript was coded line by line in NVivo (V.12). 
A constant comparison method was adopted to identify 
what characteristics participants valued when choosing 
HCPs for accessing medicines. By comparing what they 
reported valuing, we were able to identify characteristics 
they specifically appreciated in IMS and what character-
istics they valued in other providers but were missing 
in IMS. Thematic saturation was established when the 
research team discussed and agreed that no new themes 
were emerging from the data. Each excerpt indicates 
whether it is taken from an FGD or interview with visible 
medicine seller (VMS), invisible medicine seller (IMS) or 
key informant (KI).
ethics
Written informed consent was taken before conducting 
interviews or FGDs. Since some of the HCPs we inter-
viewed may have been contravening regulations by selling 
medicines, we do not name the villages selected for data 
collection to protect the anonymity of respondents.
Patient and public involvement statement
Patients/the public were not involved in designing this 
study. We plan to produce a dissemination presentation 
to help to disseminate the findings to the public.
resulTs
The first step in our study, analysis of the rapid assessment 
of community healthcare-seeking behaviour with respect 
to informal providers, indicated high use of IMS; we 
found that use of IMS was reported in 62% of all villages 
in the study khans. A total of 40 women and 20 men aged 
between 27 and 85 years participated in the 7 commu-
nity FGDs. In line with the rapid village survey, most FGD 
participants knew of IMS in their vicinity, although some 
participants in FGD 2 and 7 said that medicine sales by 
IMS no longer occurred in urban or peri-urban areas—
including in their communities—and they believed that 
this practice is now limited to rural areas. In contrast, in 
FGD_4, an elderly woman openly spoke about herself 
and a relative selling medicine from their homes and in 
FGD_6, a female said that her grandmother sells medi-
cines from home. We observed differences in opinion 
about the availability of medicines, such as antibiotics, 
from IMS within the same FGD.
Maybe at rural area (there are) grocery houses which sell 
some medicine. But we do not have that type of places 
here. (FGD_2)
They secretly do it. Sometimes people carry and sell around 
at the market and we do not know which they are and what 
sources they are from. (FGD_2)
We located ten IMS in the seven study villages (in addi-
tion to the woman in FGD_4 who sold medicines herself), 
of which five agreed to be interviewed. Only one of these 
IMS claimed to have relevant training (nursing); all of 
the others had loose links to the medical profession but 
did not have qualifications that would equip them to sell 
medicines. We identified a further 16 visible HCPs who 
sold medicines in the same villages, and interviewed all 
of them. Information about interviewees is summarised 
in table 1.
Although our study focused on IMS, we found that 
doctors—who are only allowed to stock medicines 
required for emergency care according to Cambodian 
regulations—often (secretly) sold a range of medicines, 
including antibiotics from their clinics, thereby also 
acting as medicine sellers that are difficult to identify. We, 
therefore, first present findings about factors influencing 
the choice of HCP to purchase medicines for minor 
ailments, focusing particularly on reasons for using IMS, 
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Table 1 Summary of interviewees in Khan Sen Sok and Khan Po Sen Chey
VMS: Visible medicine sellers 
(n=16; 10 females and 6 males)
Five pharmacists; one doctor running a pharmacy; two doctors who were selling medicines 
from their clinic; five medicine sellers, of which two were running outlets owned by doctors; 
one midwife; one nurse; one unqualified seller whose sister is a pharmacist (all qualifications 
were self-reported and were not verified)
IMS: Invisible medicine sellers 
(n=5, 4 females and 1 male)
One guard at a health centre; one seller who stayed with doctors during civil war; one former 
pharmaceutical sales representative; one seller whose sister took a pharmacy short course; 
one nurse
KI: Key informants from study 
villages (n=14; 5 females and 9 
males)
Four government health centre staff; four OpASHA community health workers; six village 
leaders/deputies
OpASHA, Operation ASHA.
and on different sources of trust in specific providers of 
medicine. In the final section, we report on HCPs’ knowl-
edge of the use of antibiotics, and their views on regula-
tions around medicine sales.
Factors influencing the choice of HCP to purchase medicines 
from
Trust in the effectiveness of the medicines provided
The strongest theme emerging in all FGDs and interview 
with some community health workers (KI_1, 2 and 3) 
was that when a person believed that medicines from a 
specific HCP were effective, they were likely to revisit the 
provider, regardless of cost, qualifications of the provider 
or distance, and were likely to recommend the provider 
to others. Furthermore, several participants in FGD_2 
and 3 noted that if one HCP’s medicines did not cure 
them, they would go to a different one without delay.
For me, I went and got the medicine and I got cured. For 
example, when I got swollen leg or headache, I brought 
medicine there and it was effective. So it becomes belief. 
And if it is not effective, I find another one. (female partic-
ipant in FGD_2)
Quick access to medicines at times when other health facilities 
are closed
Access to medicines at times when other health facilities 
are closed was a recurring concern among FGD partici-
pants (FGD_2, 3, 5 and 6); this was dealt with by either 
approaching IMS when there was a need for medicine at 
night or by keeping a supply of medicines at home for 
themselves and their friends or family. A female FGD 
participant, who voluntarily offered information about 
selling medicine from home, explained that she plays 
an important role because people come to her when 
they get sick at night (FGD_4). It was also reported that 
community members like to visit HCPs who sell from 
their homes because, unlike public health facilities, the 
HCP is present at all times and they do not have to wait 
(FGD_3).
Being able to get medicines even with limited means of payment
Some accounts from FGD participants and HCPs indi-
cated that people struggle with being able to purchase 
the full course medicines. In FGD_4, some participants 
spoke about using IMS because they will allow them to 
take medicines with partial payment and owe the IMS 
money until they can pay. In keeping with this theme, 
it was clear that several HCPs—visible and invisible—
perceived a demand from patients for medicines to 
be sold in small quantities due to the lack of means to 
pay, and that more qualified providers, such as pharma-
cists, may be reluctant to sell incomplete doses (VMS_9, 
IMS_11 and 15).
For those who have money, they buy drugs for two doses 
and the poorer one only buys drugs for one dose. (IMS_11)
Even if there is prescription asking them to take drugs 
from 7 or 10 days, some would ask to buy drugs for like only 
2 days … It does not matter how (much) I explained the 
situation to them … But when we don’t sell drugs to them, 
they will go and buy drugs from other places. (VMS_9, a 
qualified pharmacist running his own pharmacy)
Leniency in selling medicines to be used for animals
Another theme that emerged from a subset of the inter-
views was the use of HCPs that provide medicines for 
animals, as well as humans. Several sellers in medicine 
shops (IMS_2, VMS_3, 4, 7, 19, 20 and 21) and some 
community health workers (KI_1) said that people come 
in to buy medicines for their cattle, chickens and dogs. 
Two of the sellers (VMS_3 and 20) went on to elaborate 
that most medicines sold for animals were for chickens 
involved in cockfighting, and another reported that 
the majority of his clients purchase antibiotics over-the-
counter for their cattle and chickens.
Other factors influencing the choice of provider for purchasing 
medicines
Other factors influencing the choice of provider for 
purchasing medicines for minor ailments that we probed 
about were: cost of medicines or consultations, distance 
to travel to access HCP, level of medical qualification and 
size of health facility. These factors emerged as less salient 
in influencing decisions, and trust in the effectiveness of 
the medicine provided was the dominant consideration, 
even when cost and qualification of the HCP were specif-
ically probed about.
a
nd. Protected by copyright.
 o
n
 O
ctober 4, 2019 at The Librarian London School of Hygiene
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001787 on 20 September 2019. Downloaded from 
6 Suy S, et al. BMJ Global Health 2019;4:e001787. doi:10.1136/bmjgh-2019-001787
BMJ Global Health
I do not think whether the places belong to the public, 
the private or license or non-license. Only (whether) it is 
effective or not, then I will go and buy. I do not care about 
the price, either cheap or expensive, registered or not reg-
istered. (FGD_4)
reasons for trust in the effectiveness of medicines provided 
by the chosen HCP
We further analysed different reasons for developing 
trust in the medicines supplied by an HCP, as this was 
a very common consideration that FGD participants 
referred to.
Patient or family members’ experience during a recent illness
Trust in the effectiveness of medicines appeared to be 
most closely linked to how quickly the individual or a 
family member experienced symptomatic relief during 
a recent illness, with FGD participants (FGD_3, 5 and 
7) repeatedly using phrases such as ‘cured faster’ and 
‘reduce pain in short time’ to describe effective medi-
cines (usually referring to antibiotics). Consistent with 
this finding, we noted that some HCPs (VMS_9 and 7) 
were acutely aware of the strong patient demand for 
rapid relief and propensity to shop around. For example, 
one trained pharmacist (VMS_9) explained that he felt 
forced to dispense antibiotics because patients would 
accuse him of trying to prolong the illness to make more 
money if he gave other medicines that were perceived to 
be less effective, and felt that patients trust the opinions 
of friends and family more than the advice of the HCPs.
When the medical experts tell them to do the right thing, 
the patients don’t do and don’t believe in it. The people 
trust their peers more…. (VMS_9)
Level of training or qualification
There were contrasting findings on the extent to which 
trust in a HCP was related to whether he or she held a 
formal qualification. Participants in several FGDs indi-
cated that people generally prefer to buy medicines from 
qualified providers (FGD_1, 3, 4 and 5), usually because 
of concerns around of receiving the wrong medicine 
from HCPs who had not been adequately trained. The 
specialist training received by doctors and pharmacists 
meant that they were perceived to hold greater skills in 
correctly diagnose illnesses (FGD_2, VMS_3 and 14, KI_6 
and 9). Doctors were valued because they can ‘check the 
patient’s health’ before prescribing (FGD_5, KI_12) and 
know which medicine is correct for the symptoms (KI_9). 
One participant explained that medicine ‘is like a razor’, 
referring to the belief that it can have positive or negative 
effects depending on how it is used (FGD_1). It appeared 
that community members may look for a ‘proper sign’ or 
other visual cues to indicate that the seller is appropri-
ately trained (FGD_5 and 6).
They should have sign or logo approved by the Ministry of 
Health. They should wear white dresses to sell medicine. 
(FGD_6)
However, others said that they had trust in medicines 
provided by those who had learnt from experience just as 
much, or more, than an HCP with formal qualifications 
(FGD_3, 4 and 7).
Drug sellers are different. One has skill(s) from the school. 
Another one gets skills from experience. They can sell med-
icine from their learning and sharing with others. (FGD_3)
Access of HCP to informal sources of knowledge
Our analysis indicated that there were two main factors 
that allowed IMS to gain legitimacy and trust within 
communities as HCPs that sell effective medicines without 
being based in a health facility. The first was access to 
knowledge about medicines from family members or 
friends with relevant qualifications, such as a sister who 
has completed some pharmacy training (IMS_2). A 
participant in FGD_3 illustrated how an invisible medi-
cine seller cooperates with a doctor and how this leads to 
her being perceived as a provider of effective medicines.
[the invisible medicine seller] told the physician to write 
prescriptions and put each in each pack for different dis-
ease treatment. At night when someone knocks on her 
door and asked for diarrhoea, then she hands over a pack 
of medicine for diarrhoea. Before handing over the medi-
cine to the patient, she looks at the prescription in the bag 
to make sure that the words says for diarrhoea. Such drug 
seller is smarter than a trained seller. (FGD_3)
The second factor identified was informal medical 
training or experience, including experience during 
the Cambodian Civil War (IMS_11, FGD_4); learning 
through of their primary job working as ancillary staff 
in a hospital or health department (IMS_10, KI_10); 
or knowledge provided by pharmaceutical companies 
(KI_7, IMS_12).
Having a personal connection with the HCP and knowing that an 
HCP works in a government hospital
Finally, some participants in FGD_3 and 5 indicated that 
knowing an HCP personally can help to develop a trust 
in the medicines they provide, and several FGD partic-
ipants and a community health worker indicated that 
HCP working in a government facility helped to attract 
patients to a side business, selling medicines in the 
evening (FGD_1, 3, 4, 5 and 6; KI_1).
HCPs knowledge about antibiotics
Our study revealed potentially harmful views about the 
use of antibiotics among visible and invisible medicine 
sellers alike, including the wide range of illness antibi-
otics should be used for, and how to determine the dosing 
to use. Beliefs about the frequent need to use antibiotics 
were often related to the conceptualisation of antibiotics 
as medicines that heal a range of ailments (the Khmer 
word for antibiotics, Thnam Phsas, means ‘heal wound’) 
and that antibiotics are safe relative to other medicines 
(VMS_6, 10 and 14, IMS_11).
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The greatest detail about the (mis)use of antibiotics 
was provided, with confidence, by a female invisible 
medicine seller who learnt about medicines during the 
Khmer Rouge regime (IMS_11).
… ampicillin, amoxicillin, penicillin, used to put on 
wounds … we break them into small pieces and pour them 
on wounds on our legs. I have been in the business for 
quite a long time. That’s why I know. (IMS_11)
If you are very sick, you can take it (ampicillin) three times 
per day. If you are not that sick, you can take it for two 
times. I tell them that they must buy mixed drugs or the 
drug will only cure one symptom. You won’t cure diseases. 
For diseases like coughing, if you only take drugs for cough-
ing without antibiotics, you won’t get better. (IMS_11)
This seller was aware of the need to refer certain patients 
to the hospital, but felt that antibiotics were safe to her to 
sell. Similarly, the female invisible medicine seller iden-
tified during FDG_4 appeared to have limits around the 
number of medicines she felt confident selling, and anti-
biotics (ampicillin) was one of them.
Other IMS we interviewed were more reserved, but did 
display misconceptions, such as the need to always use 
antibiotics when someone has a cough (IMS_2) or diar-
rhoea (IMS_10), and openly admitted that they provide 
medicines based on patient demand (IMS_10, 12 and 
15). The propensity to use antibiotics at the first sign 
of common illnesses, such as cough or ‘inflammation’, 
was also found among unqualified VMS (VMS_6, 19 and 
20), as was selling of antibiotics in response to patient 
demand (VMS_3 and 5).
Mostly (best sellers are), Amok and Ampi. They mostly buy 
Amok and Ampi to use because they know these drugs. 
(VMS_3)
Some of the HCPs did share ideas about appropriate 
use of antibiotics and knowledge about antibiotic resist-
ance, referring to only selling a full dose (VMS_3), 
informing patients of the importance of completing their 
full course of treatment (VMS_4 and 6), mentioning the 
link between incomplete treatment and drug resistance 
(VMS_4, 5, 6 and 7) and explaining that antibiotics 
should not be used of minor illnesses, such as a cold 
(IMS_12, VMS_9), or to obtain profits (VMS_5 and 9).
In general, we found that doctors and trained pharma-
cists tended to focus on their responsibilities to patients 
and to avoid overprescribing, whereas IMS spoke in 
terms of providing medicines according to the patients’ 
request.
HCPs knowledge of and views on regulations around 
medicine selling
Most HCPs we interviewed, with some exceptions 
(IMS_11, VMS_17), were aware of regulations on who is 
allowed to sell medicines, such as antibiotics. We found 
two opposing views about whether existing rules that 
restricted sales of controlled medicines, such as antibi-
otics, to qualified HCPs were appropriate. Some sellers 
(VMS_6, 7, 9 and 14, IMS_11) acknowledged that they 
were not allowed to sell medicines, but justified their 
practices based on pragmatic considerations, and argued 
that the rules should allow for a wider set of providers 
(those who have done short courses or have relevant 
experience) to sell medicines legally. For example, a 
doctor who was open about selling medicines against 
regulations explained that after diagnosing a patient ‘(if) 
I don’t have drugs to sell to them, it does not make sense’ 
(VMS_7).
The other dominant view was that pharmacy training 
should be a minimal requirement to run a medicine shop 
(VMS_3 and 9, IMS_10), and that other types of training 
or on-job experience was not sufficient.
They do a short course, they are drug sellers. Yes, they can 
sell but it is not fair. Why? Because we spend 5 years or 
more and they spend only a few months and they also can 
sell. Their knowledge is very different. (VMS_3)
dIsCussIon
We provide new information about challenges faced by 
regulatory authorities in LMIC tasked with implementing 
rules that restrict access to antibiotics through licensed 
providers, specifically challenges related to the pres-
ence of HCPs that are difficult for people outside of the 
community to locate. Our study in peri-urban Cambodia 
revealed that IMS are common, they sell antibiotics 
often with dangerous misconceptions, and are trusted by 
communities as providers of effective medicine. These 
findings are relevant beyond Cambodia, as challenges 
to implementing restrictions on access to antibiotics 
through informal providers are salient in many LMIC.45 46
In all of our study villages, there were multiple HCPs 
that residents could buy medicines from, and we identi-
fied two broad factors—trust in the effectiveness of medi-
cines provided and convenience of accessing the desired 
medicines—that were most salient in influencing the 
choice. Trust emerged as a salient theme in our analysis. 
Most participants reported trusting HCPs based on how 
quickly the medicines provided were perceived to alle-
viate symptoms, and qualifications or formal licencing 
were usually secondary considerations. We found that 
this put pressure on HCPs to give multiple medications, 
including antibiotics, at the first consultation. Overmed-
ication by providing a combination of medicines that 
cover a range of symptoms—also known as polyphar-
macy—has also been found in other studies conducted 
in Cambodia36 47–49; our findings further indicate that 
informal HCPs’ access to, and use of, multiple medica-
tions at the first consultation may allow them to address 
symptoms of common illnesses without having any 
medical knowledge, thereby building trust in them and 
gaining popularity.
Relating our findings to Möllering’s conceptualisation 
of trust, we identified rational justifications based on 
perceptions of effective symptomatic relief, which link to 
his two elements of expectation and interpretation. We 
also identified his third component known as suspension, 
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as some community members indicated an emotional 
basis of trust associated with having a personal connec-
tion to the HCP.
Apart from trust, the main reason for using IMS is 
the gap they fill in existing health services by supplying 
medicines at night time, being flexible in taking delayed 
payments, giving incomplete courses of medicines when 
patients cannot afford a full course and knowingly selling 
human antibiotics for animal use. These are the features 
demanded by patients but rarely available in formal or 
visible HCPs.
Although we identified a substantial number of IMS 
in our study villages, and successfully implemented a 
novel methodology for doing so, we acknowledge that 
the number of interviews we were able to conduct with 
IMS was small; this was partly because half of the IMS we 
approached were not willing to be interviewed, which 
was unsurprising, due to the hidden nature of their work. 
We believe that a strength of our study was the use of 
highly skilled Cambodian researchers who were able to 
work with community members to find local IMS, and 
were able to get consent from five IMS for an interview. 
Another limitation of this study is the potential desir-
ability effect: community members and HCPs may have 
answered in a way that they believed made their views 
more favourable to researchers or other participants. 
It is likely that IMS are found more frequently in rural 
areas,50 and our results may underestimate the presence 
of and reliance on IMS. Future studies in rural Cambodia 
may provide an insightful comparison with our results.
ConClusIon
Although IMS are difficult for public health agencies 
to locate for engagement activities, it is important to 
address inappropriate dispensing of antibiotics by this 
group of HCPs. To reduce community use of informal 
HCPs that facilitate inappropriate access to antibiotics, 
public health services must fill some of the gaps that 
these providers are currently addressing, such as access to 
medicines at night. However, in taking steps to improve 
appropriate access to antibiotics, public health services 
will not and should not provide antibiotics primarily to 
meet patients’ expectations. Therefore it is also critical to 
reduce community demand for unnecessary antibiotics.
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